Study Testing App to Ease Anxiety Opens Nationwide Enrollment

Study Testing App to Ease Anxiety Opens Nationwide Enrollment

The first-of-its-kind Vicore COMPANION Study is now recruiting participants across the U.S. to test Almee, a new artificial intelligence (AI) app designed to help people with pulmonary fibrosis (PF) manage their anxiety. Developed by Vicore Pharma, Almee is an investigational digital cognitive behavioral therapy (CBT) that uses…

With Each November, I Celebrate 3 Lives That Have Passed

The holiday season is upon us! Here in the United States, Thanksgiving was last week, and the Macy’s Thanksgiving Day Parade heralded the arrival of Santa Claus. But November, for the past two years, has been a month of loss for me. COVID-19 and transplant In March 2020, the reality…

Kinarus Explores Partnership in China to Support Its Phase 2 Trials

Kinarus Therapeutics and the Great Health Companion Group (GHCG) in China are exploring a partnership to fund further development of KIN001, Kinarus’ potential treatment for idiopathic pulmonary fibrosis (IPF). Switzerland-based Kinarus and GHCG, a subsidiary of global China conglomerate Hakim Unique Group, are also looking into ways to…

Deciding Whether to Have Kids Can Be Complicated With IPF

Being diagnosed with a chronic illness changes everything. In addition to the physical changes, patients endure emotional, mental, and social ones as well. This is especially true for those of us thrown into the chronic illness world as a young adult, when our brains have just finished developing but our…

Treatment Candidate TXR-1002 Reduces IPF Rat Model Lung Fibrosis

TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or fibrosis, in the lungs of a rat model of the disease. Its effectiveness was comparable to that of the approved IPF therapy, Ofev (nintedanib) and was consistent with findings…

Pliant’s IPF Experimental Therapy PLN-74809 Renamed Bexotegrast

PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…

Crossing America by Rail, Thanks to the Gift of New Lungs

Rail travel has long been shrouded in both mystery and romance. English novelist Agatha Christie famously wrote “Murder on the Orient Express,” a tale of intrigue involving one of her most famous characters, Hercule Poirot. American singer-songwriter Steve Goodman originally wrote and recorded “City of New Orleans,” a song about…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums